Ingenious Buddy
Invizyne Technologies (IZTC), a development-stage biomanufacturer, has filed to raise around $17M through an initial public offering.
Invizyne said in an SEC filing that it is considering offering 4.3M shares priced at $4 per share. Underwriters would be granted a 45-day option to buy up to 645K additional shares to cover any over-allotments.
Public Ventures, a subsidiary of Invizyne’s majority shareholder, MDB, is serving as underwriter. Invizyne intends to list its shares on Nasdaq under the symbol IZTC.
Last week, biotech Kyverna Therapeutics (KYTX) went public via an IPO that raised $319M.
More on biotech IPOs
Telomir Pharmaceuticals stock falls 29% following $7M IPO
Moderna-backed Metagenomi sees stock fall 31% after $94M IPO
Kyverna Therapeutics stock rallies 59% following $319M IPO